Product News May 2019


Altreno Lotion Now Available for Acne

Ortho Dermatologics launches Altreno (tretinoin) Lotion 0.05% for the treatment of acne in patients 9 years and older. Altreno was designed for women with adult acne, providing efficacy and tolerability in an elegant lotion formulation with once-daily dosing. Altreno Lotion is formulated with soluble collagen, glycerin, and sodium hyaluronate, which hydrate the skin. For more information visit

Avène XeraCalm A.D Soothes Dry Skin

Pierre Fabre Dermo-Cosmetique USA introduces new XeraCalm A.D products formulated for dry skin prone to itching and/or atopic dermatitis. The XeraCalm A.D line includes the Lipid-Replenishing Balm and the Lipid-Replenishing Cream, both with the new D.E.F.I. (Device for Exclusive Formula Integrity) pump to dispense the sterile formula and block allergens, bacteria, or air that could compromise safety and efficacy. The line also includes the Lipid-Replenishing Cleansing Oil and the new Ultra-Rich Cleansing Bar. For more information visit

Duobrii Receives FDA Approval for Psoriasis

Ortho Dermatologics announces US Food and Drug Administration approval of the New Drug Application for Duobrii (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for treatment of plaque psoriasis in adults. Duobrii provides the benefits of combination therapy with a potent topical corticosteroid and a topical retinoid. Duobrii is expected to be available in June 2019. For more information visit

Dupixent Approved for Atopic Dermatitis in Adolescents

sanofi-aventis and Regeneron Pharmaceuticals, Inc, announce US Food and Drug Administration approval of Dupixent (dupilumab) for adolescent patients aged 12 to 17 years with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent is a targeted biologic therapy that inhibits signaling of IL-4 and IL-13, which play a role in the inflammation underlying AD. It reduces the extent and severity of AD and itching. Dupixent also is indicated for adult patients with AD. For more information visit

Jeuveau Approved for Glabellar Lines

Evolus, Inc, announces US Food and Drug Administration approval of Jeuveau (prabotulinumtoxinA-xvfs), an acetylcholine release inhibitor and neuromuscular blocking agent, for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Jeuveau will be available in spring 2019. For more information visit

Ortho Dermatologics Cash-Pay Prescription Program Offers Predictable Prices

Ortho Dermatologics launches a cash-pay prescription program that will provide physicians and patients with direct access to many branded products at predictable prices ($50 to $115). The cash-pay prescription program gives patients access to treatments for acne, actinic keratosis and superficial basal cell carcinoma, barrier repair (eg, eczema treatments), wounds, and corticosteroid-responsive diseases and atopic dermatitis at a fixed price without the need for insurance, co-pay cards, or prior authorizations. After the physician issues an e-prescription, the product is shipped to the patient's home within 48 hours. Ortho Dermatologics plans to include approximately 20 products in the program over the next 18 months. There currently are 11 products available. For more information visit

The Skin Cancer Foundation Awards 3 Research Grants

The Skin Cancer Foundation announces the winners of its annual research grant awards. The foundation awarded $125,000 total to 3 separate projects to support dermatology department research and clinical studies related to skin cancer. The 2019 recipients were Stephanie Savory, MD; Shruti Naik, PhD; and Rie Takahashi, MD, PhD. For more information visit

The Skin Cancer Foundation Introduces NMSC Digital Publication

The Skin Cancer Foundation launches Carcinomas & Keratoses, a digital publication that sheds light on the most recent and important developments in keratinocyte cancers and precancers (nonmelanoma skin cancer), including basal cell carcinoma, cutaneous squamous cell carcinoma, and actinic keratosis. The publication features content written by dermatologists and the foundation's editorial team. Désirée Ratner, MD, will serve as Editor-in-Chief. For more information visit

Tremfya One-Press Injector Approved for Plaque Psoriasis

Janssen Biotech, Inc, announces US Food and Drug Administration approval of Tremfya (guselkumab), a single-dose, patient-controlled, One-Press injector for adults with moderate to severe plaque psoriasis. The One-Press injector allows patients to control the rate and pressure of their injection, and it hides the needle throughout the process. Tremfya is an IL-23 blocker administered as a 100-mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. For more information visit

If you would like your product included in Product News, please email a press release to the Editorial Office at

Next Article: